Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Halozyme Therapeutics (NASDAQ:HALO), a developer of human enzymes that alter human tissue and allow for the easier delivery of injected drugs, surged as much as 10% after receiving an analyst upgrade.

So what: After the closing bell last night Halozyme received an upgrade from research firm UBS to buy from neutral, with the firm also boosting its price target 14% to $16. Specifically, the covering analyst, Andrew Peters, honed in on Halozyme's lower risk associated with three already approved products, the recent removal of PEGPH20 from clinical hold being a positive, and the strong launch of Herceptin-SC, a subcutaneous dosing of Herceptin, which can be done in a fraction of the time as a standard infusion and for which Halozyme receives a percentage of sales from Roche.

Now what: I've said it before and I'll say it again: You need to get Halozyme Therapeutics on your watchlist. Herceptin-SC/MabThera-SC offer a big boost in patient convenience compared to an infusion, and I would suggest this combo may deliver blockbuster potential in due time, meaning Halozyme could be nearing a turn toward full-year profitability. With a robust pipeline that includes a number of big-name collaborations as well as proprietary in-house studies I suspect that Halozyme shares could have significant room to run higher over the long run.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.